| 000 | 01797 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515203222.0 | ||
| 264 | 0 | _c20100322 | |
| 008 | 201003s 0 0 eng d | ||
| 022 | _a0394-6320 | ||
| 024 | 7 |
_a10.1177/039463200902200429 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSerra, E | |
| 245 | 0 | 0 |
_aBevacizumab-related osteneocrosis of the jaw. _h[electronic resource] |
| 260 |
_bInternational journal of immunopathology and pharmacology _c |
||
| 300 |
_a1121-3 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Letter | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 |
_aAlveolar Bone Loss _xchemically induced |
| 650 | 0 | 4 |
_aAmoxicillin-Potassium Clavulanate Combination _xtherapeutic use |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aChlorhexidine _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJaw Diseases _xchemically induced |
| 650 | 0 | 4 |
_aLung Neoplasms _xpathology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMouthwashes _xadministration & dosage |
| 650 | 0 | 4 |
_aOsteonecrosis _xchemically induced |
| 650 | 0 | 4 |
_aPain _xchemically induced |
| 650 | 0 | 4 |
_aTooth Extraction _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aPaolantonio, M | |
| 700 | 1 | _aSpoto, G | |
| 700 | 1 | _aMastrangelo, F | |
| 700 | 1 | _aTetè, S | |
| 700 | 1 | _aDolci, M | |
| 773 | 0 |
_tInternational journal of immunopathology and pharmacology _gvol. 22 _gno. 4 _gp. 1121-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/039463200902200429 _zAvailable from publisher's website |
| 999 |
_c19452079 _d19452079 |
||